Clinical evaluation of sulbactam/cefoperazone in the pediatric infections
Meguro, H.; Tajima, T.; Nonaka, C.; Mashiko, J.; Fujii, R.; Arimasu, O.
Japanese Journal of Antibiotics 37(10): 1821-1830
1984
ISSN/ISBN: 0368-2781 PMID: 6094862 Document Number: 225077
Sulbactam/cefoperazone (SBT/CPZ), a fifty-fifty combination of a beta-lactamase inhibitor, SBT, and an already marketed broad spectrum cephalosporin, CPZ, was evaluated for its efficacy and safety in 25 children. The diagnoses included purulent lymphadenitis, pneumonia, acute UTI, bacteremia and purulent meningitis. SBT/CPZ was effective in all the 20 cases with bacterial infections, but strains highly resistant to CPZ were not isolated in this study. The serum and cerebrospinal-fluid levels of SBT were grossly parallel with those of CPZ, and the half-life of the serum SBT was 0.754 hour. Although severe adverse reactions were not encountered with SBT/CPZ therapy, loose stools in 20% and diarrhea in 16% of the cases were observed.